<DOC>
	<DOCNO>NCT00416377</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill cancer cell . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This clinical trial study well radiation therapy combination chemotherapy work treat young patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Radiation Therapy Combination Chemotherapy Treating Young Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Maintain present satisfactory result patient treated protocol UKCCSG-HD-8201 pediatric patient stage I-III Hodgkin 's lymphoma treat radiotherapy combination chemotherapy comprise chlorambucil , procarbazine hydrochloride , prednisolone , vinblastine follow doxorubicin hydrochloride , bleomycin , vincristine , dacarbazine . - Determine , comparison UKCCSG-HD-8201 , mediastinal irradiation safely omit management pediatric patient Hodgkin 's lymphoma bulky mediastinal disease . - Determine gallium scan mediastinum chemotherapy identify patient residual active mediastinal disease . - Improve disease control patient stage IV Hodgkin 's lymphoma slow responder intensify treatment patient fail achieve complete remission 4 course chlorambucil , vinblastine , procarbazine hydrochloride , prednisone . OUTLINE : This multicenter study . Patients stratify accord stage disease ( I vs II-IV ) . - Stage I : Patients undergo involved-field radiotherapy . - Stage II-IV : - CHLVPP chemotherapy : Patients receive CHLVPP chemotherapy comprise oral chlorambucil , oral procarbazine hydrochloride , oral prednisolone day 1-14 vinblastine IV day 1-8 . Treatment repeat every 28 day 2 course . Patients achieve complete resolution ( CR ) measurable disease receive additional 4 course CHLVPP . Patients response progressive disease proceed ABVD chemotherapy . Patients shrinkage measurable disease &lt; 50 % original dimension ( GPR ) receive 2 additional course CHLVPP . Patients achieve CR GPR completion 2 additional course CHLVPP receive 4 course CHLVPP . Patients achieve shrinkage measurable disease â‰¥ 50 % original dimension ( PR ) 2 additional course CHLVPP OR patient achieve CR total 8 course CHLVPP proceed ABVD chemotherapy . - ABVD chemotherapy : Patients receive ABVD chemotherapy comprise doxorubicin hydrochloride IV 4 hour bleomycin IV , vincristine IV , dacarbazine IV day 1 15 . Treatment repeat every 28 day 4-6 course absence disease progression unacceptable toxicity . - Mediastinal mass : Patients receive chemotherapy per stage II-IV . Patients present airway superior vena cava obstruction may also undergo radiotherapy . Patients achieve CR completion chemotherapy receive treatment . Patients achieve GPR PR completion chemotherapy undergo gallium scan CT scan thorax without biopsy investigator 's discretion . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 353 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm childhood Hodgkin 's lymphoma lymph node biopsy Any stage disease Patients bilateral upper cervical disease evidence supraclavicular , thoracic inlet , Waldeyers ring involvement treat stage I disease PATIENT CHARACTERISTICS : Platelet count &gt; 100,000/mm^3 Absolute neutrophil count &gt; 1,000/mm^3 PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>